CoChat

Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer

Open access
Yu, Irene, Dakwar, Anthony, Takabe, Kazuaki · 2023 · Cells

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Abstract

Immunotherapy in colorectal cancer (CRC) has made great strides within the past decade. Immune checkpoint inhibitors are a class of immunotherapy and have been shown to greatly improve patient outcomes in mismatch repair-deficient (dMMR) CRC. Now, they are part of the standard of care for this subset of CRC. Because of this, there has been a growing interest in the efficacy and timing of immunotherapy for other subsets of CRC, including locally advanced, metastatic, and microsatellite stable (MSS). In this review, we aim to examine the three main classes of immunotherapy for CRC—immune checkpoint inhibitors (ICIs), adoptive cell transfer therapy (ACT), and tumor vaccines—and discuss the most recent advances and future directions for each.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells12020258

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The principle of immunoexclusion is based on the concept that tumors can be hot, cold, or excluded based on the location and density of T cells in the tumor core and/or invasive margin of the tumor, which is defined as a 1 mm region centered on the interface of malignant cells and normal host cells. (A). Hot tumors have high T-cell density in the core of the tumor. (B). Cold tumors have low T-cell density in the core and invasive margin of the tumor. (C). Excluded tumors have high T-cell density only in the invasive margin of the tumor.
Figure 1 The principle of immunoexclusion is based on the concept that tumors can be hot, cold, or excluded based on the location and density of T cells in the tumor core and/or invasive margin of the tumor, which is defined as a 1 mm region centered on the interface of malignant cells and normal host cells. (A). Hot tumors have high T-cell density in the core of the tumor. (B). Cold tumors have low T-cell density in the core and invasive margin of the tumor. (C). Excluded tumors have high T-cell density only in the invasive margin of the tumor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 99 references

Cited by

See all 41

Metadata

Authors
Yu, I., Dakwar, A., & Takabe, K.
Affiliations
Roswell Park Comprehensive Cancer Center (US)
Corresponding author
Takabe, Kazuaki
Venue
Cells
Publisher
MDPI AG
Published
2023-01-08
Volume
12
Issue
2
Pages
258
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4313825882
Cited by
40
References
99
Citations by year
2026: 7 · 2025: 16 · 2024: 8 · 2023: 9
FWCI
1.29
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health, USA (P30 CA016056/CA/NCI)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
colorectal cancer, immunotherapy, immune checkpoint inhibitors, mismatch repair deficiency, neoadjuvant therapy, adjuvant therapy, primary treatment, metastatic colorectal cancer, locally advanced colorectal cancer, microsatellite stable colorectal cancer, adoptive cell transfer, cancer vaccines
MeSH terms
Immune Checkpoint Inhibitors, Adjuvants, Immunologic, Adjuvants, Pharmaceutic, Brain Neoplasms, Humans, Immunotherapy, Neoplastic Syndromes, Hereditary, Colorectal Neoplasms, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cells12020258
The paper
Yu, I., Dakwar, A., & Takabe, K. (2023). Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. Cells. https://doi.org/10.3390/cells12020258

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.